Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 14:13:1509-1514.
doi: 10.2147/IJGM.S284952. eCollection 2020.

Pump Proton and Laryngeal H+/K+ ATPases

Affiliations
Review

Pump Proton and Laryngeal H+/K+ ATPases

Zhe Zhang et al. Int J Gen Med. .

Abstract

Purpose: The presence of extra-gastric H+/K+ ATPases may explain the clinically significant effect of proton pump inhibitor (PPI) pharmacotherapy in patients with chronic laryngitis related to laryngopharyngeal reflux disease (LPRD) but without gastroesophageal reflux disease (GERD) symptoms. Given the need for a better understanding of GERD and LPRD, we review the various proton pumps with respect to their classification, function, and distribution. We then consider the potential role of the laryngeal H+/K+ ATPase pump in LPRD.

Methods: We searched databases of PubMed, EMBASE, and Web of Science to achieve related published before September 15, 2020.

Results: There were only seven English-literatures meeting inclusive criteria about laryngeal H+/K+ ATPases. Some studies provide convincing evidence of a laryngeal H+/K+ ATPase in normal laryngeal tissues but also suggest the potential role of the proton pump in the abnormal mucus secretion frequently seen in patients with chronic laryngitis.

Conclusion: A laryngeal H+/K+ ATPase expresses in normal laryngeal tissues. These findings question the current understanding of GERD and LPRD.

Keywords: H+/K+ ATPases; chronic laryngitis; gastroesophageal reflux disease; laryngopharyngeal reflux disease; larynx; proton pump.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Gastric proton pump H+/K+ ATPase and its functions. The gastric H+/K+ ATPase mediates the transport of K+ ions in the extracellular fluid into the cell, while intracellular H+ ions are simultaneously pumped out of the cell against a high concentration gradient to complete ion transport and gastric acid secretion. H+/K+ ATPase activity is stimulated by inflammatory and other factors by the bacterium Helicobacter pylori, leading to excessive gastric acid secretion and GERD. This is the mechanism targeted by PPI therapy. H+/K+ ATPases contain the α-subunit and β-subunit. The α-subunit is made up of 1035 amino acids. ATP-binding, acyl-phosphorylation, inhibitor-binding, and ion-recognition sites are included in the α-subunit. The 290-amino-acid β-subunit is responsible for enzyme assembly and plays a role in enzyme activity.
Figure 2
Figure 2
Laryngeal H+/K+ ATPases. The H+/K+ ATPase proton pump is located mainly in the laryngeal seromucinous glands and ducts rather than in the squamous epithelium, which may be responsible for regulating seromucinous secretion in two conditions: (1) direct acid reflux in LPRD, (2) first-stage reflux, when reactivation during subsequent acid exposure leads to pepsin binding and thus to tissue autodigestion, which together with cellular necrosis regulates the pH of the interstitium and may lead to laryngopharyngeal reflux-induced acid exposure. The laryngeal H+/K+ ATPase is activated by laryngopharyngeal reflux and other infectious or inflammatory stimuli. The laryngeal H+/K+ ATPase secretes low levels of acid, which may induce laryngeal damage and, subsequently, chronic laryngitis or other laryngeal diseases. The pathologically acidic environment of the oropharynx in patients without gastroesophageal reflux is effective for PPI therapy, as the larynx is one of the extragastric targets of these drugs.

Similar articles

Cited by

References

    1. Lechien JR, Saussez S, Karkos PD. Laryngopharyngeal reflux disease: clinical presentation, diagnosis and therapeutic challenges in 2018. Curr Opin Otolaryngol Head Neck Surg. 2018;26(6):392–402. doi:10.1097/MOO.0000000000000486 - DOI - PubMed
    1. Wong MW, Bair MJ, Chang WC, et al. Clinical and psychological characteristics in gastroesophageal reflux disease patients overlapping with laryngopharyngeal reflux symptoms. J Gastroenterol Hepatol. 2019;34(10):1720–1726. doi:10.1111/jgh.14651 - DOI - PubMed
    1. Lechien JR, Akst LM, Hamdan AL, et al. Evaluation and management of laryngopharyngeal reflux disease: state of the art review. Otolaryngol Head Neck Surg. 2019;160(5):762–782. doi:10.1177/0194599819827488 - DOI - PubMed
    1. Tan JJ, Wang L, Mo TT, et al. Pepsin promotes IL-8 signaling-induced epithelial-mesenchymal transition in laryngeal carcinoma. Cancer Cell Int. 2019;19(1):64. doi:10.1186/s12935-019-0772-7 - DOI - PMC - PubMed
    1. Sasaki CT, Toman J, Vageli D, Sethi G. The in vitro effect of acidic-pepsin on nuclear factor kappa B activation and its related oncogenic effect on normal human hypopharyngeal cells. PLoS One. 2016;11(12):e0168269. doi:10.1371/journal.pone.0168269 - DOI - PMC - PubMed